Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. European Respiratory Journal. 2020: 55(6).

Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJO, Downer NJ, et al. Local anaesthetic thoracoscopy: British thoracic society pleural disease guideline 2010. Thorax. 2010;65(2):ii54-60.

PubMed  Google Scholar 

Sundaralingam A, Aujayeb A, Jackson KA, Pellas EI, Khan II, Chohan MT, et al. Investigation and outcomes in patients with nonspecific pleuritis: results from the International Collaborative Effusion database. ERJ Open Res. 2023;9(2).

Karpathiou G, Péoc’h M, Sundaralingam A, Rahman N, Froudarakis ME. Inflammation of the Pleural Cavity: A Review on Pathogenesis, Diagnosis and Implications in Tumor Pathophysiology. Cancers. 2022;14(6):1415.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Reuter SB, Clementsen PF, Bodtger U. Incidence of malignancy and survival in patients with idiopathic pleuritis. J Thorac Dis. 2019;11(2):386–92.

Article  PubMed  PubMed Central  Google Scholar 

Ferguson K, Neilson M, Mercer R, King J, Marshall K, Welch H, et al. Results of the Meso-ORIGINS feasibility study regarding collection of matched benign-mesothelioma tissue pairs by longitudinal surveillance. BMJ Open. 2023;13(8):e067780.

Article  PubMed  PubMed Central  Google Scholar 

Karpathiou G, Anevlavis S, Tiffet O, Casteillo F, Mobarki M, Mismetti V, et al. Clinical long-term outcome of non-specific pleuritis (NSP) after surgical or medical thoracoscopy. J Thorac Dis. 2020;12(5):2096–104.

Article  PubMed  PubMed Central  Google Scholar 

Deschuyteneer EP, De Keukeleire T. Diagnostic value and safety of thoracoscopic pleural biopsies in pleural exudative effusions of unknown origin, including follow-up. BMJ Open Respir Res. 2022;9(1):e001161.

Article  PubMed  PubMed Central  Google Scholar 

Yu YX, Yang Y, Wu YB, Wang XJ, Xu LL, Wang Z, et al. An update of the long-term outcome of patients with nonspecific pleurisy at medical thoracoscopy. BMC Pulm Med. 2021;21(1).

Davies HE, Nicholson JE, Rahman NM, Wilkinson EM, Davies RJO, Lee YCG. Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. Eur J Cardiothorac Surg. 2010;38(4):472–7.

Article  PubMed  Google Scholar 

Aujayeb A, Jackson K. A review of the outcomes of rigid medical thoracoscopy in a large UK district general hospital. Pleura Peritoneum. 2020;5(4):20200131.

Article  PubMed  PubMed Central  Google Scholar 

Ferguson K, Blyth KG. Benign Pleural Thickening, Fibrosis and Plaques. In: James S, editors. Encyclopaedia of Respiratory Medicine. 2nd Edition. Elsevier Ltd: 2022.

Xiang Z, Deng X, He W, Yang Q, Ni L, Dehghan Shasaltaneh M, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med. 2022;54(1):1357–71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Acencio MMP, Puka J, Alvarenga VA, Martins V, de Carvalho MLP, Marchi E, et al. Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion. Oncotarget. 2017;8(62):105093.

Article  PubMed  PubMed Central  Google Scholar 

Mutsaers SE, Prele CM, Brody AR, Idell S. Pathogenesis of pleural fibrosis. Respirology. 2004;9(4):428–40.

Article  PubMed  Google Scholar 

Karpathiou G, Hathroubi S, Patoir A, Tiffet O, Casteillo F, Brun C, et al. Non-specific pleuritis: pathological patterns in benign pleuritis. Pathol 2019 Aug. 51(4):405–11.

Google Scholar 

Ferguson K, Neilly MDJ, Roche J, Tate M, Blyth KG, of British Thoracic Oncology Group. Mesothelioma Evolution Following a Diagnosis of Benign Pleural Inflammation. Poster session presented at 22nd Annual Meeting ; 2024 April 17; Belfast.

Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology. 2017;6(2):e1278330.

Article  PubMed  PubMed Central  Google Scholar 

Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, et al. Evaluation of clonal origin of malignant mesothelioma. J Transl Med. 2014(1).

Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472–86.

Article  PubMed  PubMed Central  Google Scholar 

de Fonseka D, Arnold DT, Smartt HJM, Culliford L, Stadon L, Tucker E, et al. PET-CT-guided versus CT-guided biopsy in suspected malignant pleural thickening: a randomised trial. Eur Respir J. 2024;63(2):2301295.

Article  PubMed  PubMed Central  Google Scholar 

Harber J, Kamata T, Pritchard C, Fennell D. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy. J Immunother Cancer. 2021;9(9):3032.

Article  Google Scholar 

Asciak R, Kanellakis NI, Yao X, Abd Hamid M, Mercer RM, Hassan M, et al. Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation. Front Oncol. 2021;11. https://doi.org/10.3389/fonc.2021.658395.

Hegmans J, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J. 2006;27(6):1086–95.

Article  PubMed  CAS  Google Scholar 

Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S, et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res. 2016;22(12):3087–96.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol. 1992;9(2):151–61.

PubMed  CAS  Google Scholar 

Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, et al. Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol. 2019;33(2):297–302.

Article  PubMed  Google Scholar 

Sauter JL, Dacic S, Galateau-Salle F, Attanoos RL, Butnor KJ, Churg A et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022: 17(5): 608 – 22.

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016: 48(4): 407 – 16.

Kukuyan AM, Sementino E, Kadariya Y, Menges CW, Cheung M, Tan Y, et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of Pleural Malignant Mesothelioma in conditional mouse models. Cancer Res. 2019;79(16):4113–23.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dacic S, Roy S, Lyons MA, von der Thusen JH, Galateau-Salle F, Churg A. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ. Lung Cancer. 2020;149:1–4.

Article  PubMed  Google Scholar 

Wang LM, Shi ZW, Wang JL, Lv Z, Du F, Bin, Yang Q, Bin, et al. Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis. Oncotarget. 2017;8(40):68863–72.

Article  PubMed  PubMed Central  Google Scholar 

Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between Sarcomatoid Mesothelioma and Fibrous Pleuritis. Am J Clin Pathol. 2013;139(1):39–46.

Article  PubMed  CAS  Google Scholar 

Marshall K, Jackson S, Jones J, Holme J, Lyons J, Barrett E, et al. Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer. 2020;150:195–200.

Article  PubMed  Google Scholar 

Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, et al. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer. 2017;104:98–105.

Article  PubMed  Google Scholar 

Klebe S, Nakatani Y, Dobra K, Butnor KJ, Roden AC, Nicholson AG, et al. The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology. 2021;53(4):446–53.

Article  PubMed  Google Scholar 

Currie GP, Watt SJ, Maskell NA. New definition of diffuse Pleural Thickening for Industrial Injuries benefits claims. BMJ. 2023;339(7719):506–10.

Google Scholar 

Fujimoto N, Gemba K, Aoe K, Kato K, Yokoyama T, Usami I, et al. Clinical Investigation of Benign Asbestos Pleural Effusion. Pulm Med. 2015;416179.

Miles SE, Sandrini A, Johnson AR, Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: a review. J Occup Med Toxicol. 2008;3(1):20.

Article  PubMed  PubMed Central  Google Scholar 

Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP et al. British Thoracic Society Guideline for pleural disease. Thorax. 2023: 78(3): S1-42.

Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med. 2011(6):518–26.

Article  Google Scholar 

Maskell NA, Davies CWH, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. Controlled trial of intrapleural Streptokinase for pleural infection. N Engl J Med. 2005;352(9):865–74.